Brief: Reduced Usage Of Ranitidine, Lockdown Could Impact Revenues Of SMS Lifesciences India

Haleos Labs

09/04/2020 15:02

April 9 (Reuters) - SMS Lifesciences India Ltd  SMSL.NS :
    * UPDATE ON RANITIDINE HCL
    * RANITIDINE HCL OCCUPIES MAJOR CONTRIBUTION IN ASPECT OF
BOTH
"VOLUMES AS WELL AS VALUE" FOR CO
    * CO DOES NOT HAVE ANY RANITIDINE API SALES TO U.S. MARKET
EITHER
DIRECTLY OR INDIRECTLY
    * USAGE OF RANITIDINE TABLETS COULD REDUCE, REPERCUSSIONS OF
SAME
ALONG WITH LOCKDOWN DUE TO PANDEMIC DIFFICULT TO ASSESS
CURRENTLY
    * REDUCED USAGE OF RANITIDINE, LOCKDOWN COULD IMPACT
REVENUES OF
CO

Source text for Eikon:  ID:nBSEx4Rml 
Further company coverage:  SMSL.NS 

 ((Reuters.Briefs@thomsonreuters.com;))